| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
CAMBRIDGE, U.K.—Metrion Biosciences, a specialist ion channel contract research and drug discovery company, recently announced it has been awarded £637,000 funding under the Innovate UK Biomedical Catalyst Primer Award scheme. The funding will be used to support further research on orally available potassium channel inhibitors for treatment of psoriasis, a common auto-immune disease for which improved treatments are much needed.
 
The project commenced in September, focusing on the further optimization of a set of key compounds, and their characterization in disease relevant models. The compounds are taken from the portfolio acquired by Metrion in January this year of more than 2,000 small-molecule inhibitors of a voltage-gated potassium channel known to be involved in the development of auto-immune disease. Metrion has already confirmed the potent in-vitro activity of the selected key compounds, and has filed a new patent application covering a series of these active drug leads.
 
If successful, the project may lead to the selection of one or more novel oral drug candidates suitable for development as potential new therapeutics for the treatment of psoriasis and other autoimmune disorders.
 
Psoriasis is a long-lasting autoimmune disease which affects more than 100 million people worldwide, characterized by patches of abnormal skin, which are typically red, dry, itchy and scaly. There exists a low level of satisfaction with existing treatment standards, with 57 percent of oral and 45 percent of biologic therapy recipients discontinuing therapy for reasons of safety/tolerability or lack/loss of efficacy.

Related Topics

Published In

Volume 14 - Issue 11 | November 2018

November 2018

November 2018 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
A 3D-rendered illustration of a eukaryotic cell highlighting organelles such as the nucleus, endoplasmic reticulum, mitochondria, and cytoskeletal structures in pink and purple tones.

Shining light on the subcellular proteome

Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue